Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study

Flibanserin (FLB) was approved by FDA for the treatment of pre-menopausal female hypoactive sexual desire disorder (HSDD). FLB suffers from low oral bioavailability (33%) which might be due to hepatic first-pass metabolism in addition to its poor aqueous solubility. The sublingual route could be a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Naguib, Marianne J., Makhlouf, Amal I. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238064/
https://www.ncbi.nlm.nih.gov/pubmed/34176378
http://dx.doi.org/10.1080/10717544.2021.1938755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238064/
https://www.ncbi.nlm.nih.gov/pubmed/34176378
http://dx.doi.org/10.1080/10717544.2021.1938755

Ejemplares similares